Current Research Gaps in Critical Care Pharmacy for 2026
The most critical research gaps in critical care pharmacy for 2026 center on generating high-quality evidence for pharmacotherapy recommendations, establishing optimal therapeutic drug monitoring protocols, demonstrating real-world clinical impact of personalized dosing strategies, and defining ideal practice models that balance direct patient care with research activities.
Primary Evidence Gaps
Quality of Evidence Supporting Clinical Recommendations
The fundamental problem remains that only one-third of strong critical care pharmacotherapy recommendations are supported by highest-quality evidence 1. This 2010 analysis revealed that two-thirds of critical care pharmacotherapy guidelines could not be recommended without alterations or were not recommended at all, with particularly poor quality guidelines addressing penetrating brain injury, SARS, and hemodynamic support of sepsis 1.
While this analysis is dated, the structural problems it identified—poor applicability, inadequate stakeholder involvement, and lack of editorial independence—likely persist and represent ongoing gaps requiring systematic research to address.
Therapeutic Drug Monitoring Implementation and Outcomes
Despite growing evidence supporting therapeutic drug monitoring (TDM) for beta-lactam antibiotics, the clinical impact on patient mortality and morbidity is not yet fully demonstrated 2. The 2019 French guidelines acknowledge this critical gap, recommending TDM while simultaneously noting that large randomized clinical trials are still needed 2.
Key unanswered questions include:
- Optimal concentration targets for different patient populations and infection sites
- Frequency of monitoring required to capture intra-individual variability (which can reach 30-129% over just 4 days) 2
- Cost-effectiveness of routine TDM implementation
- Impact on antimicrobial resistance patterns
Real-World Evidence for Personalized Dosing
The massive pharmacokinetic variability in critically ill patients (concentrations varying by a factor of 100 between patients) 2 demands individualized dosing, yet prospective studies demonstrating improved mortality, reduced length of stay, or better quality of life outcomes with personalized approaches remain insufficient 2.
Research is needed to:
- Validate PK-PD targets (current recommendation: free plasma concentration 4-8× MIC for 100% of dosing interval) 2
- Compare continuous versus intermittent infusion strategies across diverse patient populations
- Establish protocols for dose adjustment in patients on extracorporeal therapies
Practice Model and Resource Allocation Gaps
Optimal Pharmacist Staffing and Time Allocation
Critical care pharmacists identify ideal CCP-to-patient ratios of 1:11-15 (49.8%) or 1:16-20 (33.9%), with 50% of time dedicated to direct patient care 3. However, research demonstrating how these ratios impact patient outcomes (mortality, medication errors, adverse drug events) is lacking.
The 2023 UK survey revealed that only 12.7% of critical care pharmacists have both research capability (postgraduate qualification) and opportunity (dedicated research time) 4. Those with both produced significantly more research outputs (median 4 vs 0, P=0.023) 4, highlighting a structural barrier that perpetuates the evidence gap.
Research Capacity Building
The most frequently reported barrier to research is time (71.4% of pharmacists), with only 13.3% having research mentors 4. This creates a vicious cycle where lack of research capacity prevents generation of evidence needed to justify dedicated research time.
Emerging Priority Areas for 2026
Value-Based Care Models
Real-world evidence to inform managed care pharmacy decision-making and value-based models addressing total cost of care represent critical gaps 5. Research must demonstrate how critical care pharmacy services impact:
- Hospital readmission rates
- Long-term functional outcomes
- Healthcare utilization costs
- Quality-adjusted life years
Impact of Pharmacy Interventions on Patient-Centered Outcomes
While the 2020 position papers outline 82 recommendations for critical care pharmacy practice 6, 7, evidence linking specific pharmacy interventions to improvements in mortality, morbidity, and quality of life remains insufficient. Research should focus on:
- Direct patient care services provided by critical care pharmacists
- Benefit design and utilization management strategies
- Quality improvement initiatives and medication safety programs
Pharmacoequity in Critical Care
The 2025 pharmacoequity framework 8 highlights a completely unexplored area in critical care pharmacy: systematic measurement and reduction of disparities in medication access, adherence, and monitoring across different patient populations. No studies have examined whether pharmacokinetic variability, TDM access, or personalized dosing strategies are equitably distributed across racial, ethnic, or socioeconomic groups in the ICU.
Methodological Gaps
Guideline Development Quality
Guidelines must adopt GRADE methodology and ensure transparent links between evidence quality and recommendation strength 1. The applicability domain (organizational, behavioral, and cost implications) consistently scores lowest and requires focused research attention 1.
Sustainability and Implementation Science
Guidelines have a lifespan and require continuous redevelopment and reimplementation 9. Research on effective implementation strategies, barriers to adoption, and methods for maintaining guideline currency in rapidly evolving critical care environments is critically needed.
Common Pitfalls to Avoid
- Conducting research without adequate capability and opportunity: Institutions must provide dedicated research time and mentorship 4
- Focusing solely on surrogate endpoints: Studies must measure mortality, morbidity, and quality of life, not just PK-PD target attainment
- Ignoring intra-individual variability: Single-timepoint TDM studies miss the 30-129% variability over days 2
- Developing guidelines without patient input: Stakeholder involvement consistently scores low 1
The research agenda for 2026 must prioritize pragmatic trials demonstrating clinical impact of personalized pharmacotherapy, establish sustainable research infrastructure within critical care pharmacy practice, and address equity in medication optimization strategies.